|
|
  |
|
 |
|     |
|
||||
|
||||
|
||||
|
||||
|
||||
|
Scientific Publications of the DCP: Bibliography 2000
Office of the Director:Greenwald, P. Prevention of neoplasia. In Humes, HD,DuPont, HL, et al, Eds. Kelley's Textbook of Internal Medicine. 4th Edition.Chapter 22. Philadelphia: Lippincott Williams & Wilkins, 2000:155-159. Greenwald, P, Milner, JA, Clifford, CK. Creating a new paradigm in nutrition research within the National Cancer Institute [Issues and Opinions]. Journal of Nutrition, 2000;130:3103-3105. Kaluzny, A. Managing a health care alliance. Reprint ed. Preface by Greenwald, P & Ford, L. Washington: Beard, 2000. Kelloff GJ, Sigman CC, Johnson KA, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37. Review.  Office of Preventive Oncology: (Staff & Fellows)Anderson,WF, Reeves, JE, Elias, A, Berkel, HJ. Outcome of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer, 2000;88(1):95-107. Anderson, WF,Chu, KC, Chatterjee, N, Brawley,O, Brinton, L. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results Database. Journal of Clinical Oncology, 2001;19(1):18-27. Augustson, EM, Dougher, MJ, Markham, MR. Emergence of conditional stimulus relations and transfer of respondent eliciting functions among compound stimuli. The Psychological Record, 2000; 50(4):745-770. Edwards, R, Augustson, EM, Fillingim, R. Sex-specific effects of pain related anxiety on adjustment to chronic pain. The Clinical Journal of Pain, 2000; 16:46-53. Huey, RB, Gilchrist, GW, Carlson, ML, Berrigan, D, Serra, L. Rapid evolution of a geographic cline in size in an introduced fly. Science, 2000;287(5451):308-309. Berrigan, D. Correlations between measures of thermal stress resistance within and between species. Oikos 2000;89:301-302. Hercus, MJ, Berrigan, D, Blows, D, Magiafoglou, MW, Hoffmann, A. Resistance to temperature extremes between and within life cycle stages in Drosophila serrata, D. birchii and their hybrids: intraspecific and interspecific comparisons. Biological Journal of the Linnean Society, 2000;71:(3) 403-416. Gasser, M, Kaiser, M, Berrigan, D, Stearns, SC. Life history correlates of evolution under high and low adult mortality. Evolution, 2000;54:1260-1272. Colbert, LH, Hootman, JM, Macera, CA. Injuries in walkers and runners in the Aerobics Center Longitudinal Study. Clinical Journal of Sport Medicine, 2000;10(4):259-263. Colbert, LH, Davis, JM, Essig, DA, Ghaffar, A, Mayer, EP. Exercise and tumor development in a mouse predisposed to multiple intestinal adenomas. Medicine and Science in Sports and Exercise, 2000;32(10):1704-1708. Poetschke, HL, Klug, DB, Perkins, SN, Wang, TT, Richie, ER, Hursting, SD. Effects of calorie restriction on thymocyte growth, death and maturation. Carcinogenesis, 2000;21(11):1959-1964. Shen, JC, Klein, RD, Wei, Q, Guan, Y, Wang, TTY, Hursting, SD. Low-dose genistein induces cyclin-dependnet kinase inhibitors and G1 cell cycle arrest in human prostate cancer cells. Molecular Carcinogenesis. 2000;29:92-102. Hursting, SD. Nutritional modulation of the carcinogenesis process: targets and examples. In:Mason J & Nitenberg G, eds. Cancer and Nutrition: Prevention and Treatment, Nestle Nutrition Workshop Series, Clinical and Performance Programme, Volume 4, 2000;1-21. Chang, S, Hursting, SD, Contois, JH, Strom, SS, Yamamura, Y, Troncoso, P, Babaian, R, Wheeler, T, Amos, CI, Spitz, MR,.Leptin and prostate cancer. The Prostate, 2001;46:62-67. Jennings-Dozier, K & Lawrence, D. Sociodemographic predictors of cervical cancer screening adherence in minority women. Cancer Nursing, 2000;24(4):350-358. Mahon, S, Jennings-Dozier, K.(Associate Editors) Cancer prevention, early detection supplements. Supplement to Oncology Nursing Forum, 2000;27(9):3-63. Goodman, JE, Lavigne, JA, Hengstler, JG, Tanner, B, Helzlsouer, KJ, Yager, JD. Catechol-O-methyltransferase polymorphism is not associated with ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 2000, Dec 9(12):1373-1376. Heath, E, Limburg, P, Hawk, E, Forastiere A. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology, 2000;14:507-514. Limburg, PJ, Ahlquist, DA, Roche, PC, Klee, GG, Harrington, JJ/ Immunodiscrimination of colorectal neoplasia using MUCI antibodies: discrepant findings in tissue versus stool. Digestive Diseases Science, 2000; 45:494-499. Limburg, PJ. Ahliquist, DA, Sandborn, WJ, Harrington, JJ, Mahoney, DW, Devens, ME, Zinsmeister, AS. Fecal calprotectin levels predict colorectal inflamation among colonoscopy patients with unexplained chronic diarrhea. American Journal of Gastroenterology, 2000; 95:2831-2837. Mai, V, Wiegel, J, Lorenz, W. Cloning and expression of a novel bifunctional xylosidase/arabinosidase from Thermoanaerobacter ethanolicus JW200. Gene, 2000;247:137-143 Moore, DB, Folsom, AR, Mink, PJ, Hong, CP, Anderson KE, Kushi LH. Physical activity and incidence of postmenopausal breast cancer. Epidemiology, 2000;11:292-296. Lazovich, D, Thompson, JA, Mink, PJ, Sellers, TA, Anderson, KE. Induced abortion and breast cancer risk. Epidemiology, 2000;11:76-80. Misra, RR, Pinsky, PF, Srivastava, S. Prognostic factors for hematologic cancers. Hematology/Oncology Clinics of North America. 2000;14:907-924. Misra, RR, Tangrea, JA, Virtamo, J, Ratnasinghe, D, Andersen, MR, Barrett, M, Taylor, PR, Albanes, D.:Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Letters, 2001; 64:161-167. O'Mara, AM. Communication and the new nurse: autonomy with responsibility. In: Arnold E, Boggs K, Eds. Interpersonal Relationships. Professional Communication Skills for Nurses,3rd edition, Philadelphia:W.B. Saunders, 2000. O'Mara ,AM, Whedon, MB. Nursing assessment: hematologic system. In: Lewis SM, Heitkemper MM, Dirksen SR, Eds. Medical-surgical Nursing. Assessment and Management of Nursing Problems, 5th Edition, St. Louis:Mosby, 2000. O'Mara, AM, Bernstein S. Neoplasia. In: Thompson JM, McFarland GK, Hirsch JE, Tucker S, Eds. Mosby's Clinical Nursing, 4th Edition, St. Louis:Mosby-Year Book, Inc, 2001. Hogan, C, Lynn, J, Gabel, J, Lunney, J, O'Mara, A, Wilkinson, A. A statistical profile of decedents in the Medicare program. Washington, DC, Medicare Payment Advisory Commission, 3/7/2000;1-53. Parascandola, M. Cigarettes and the US Public Health Service in the 1950s. American Journal of Public Health, 2001;91:196-206. Poetschke, HL, Klug, DB, Perkins, SN, Wang, TT, Richie, ER, Hursting, SD. Effects of calorie restriction on thymocyte growth, death and maturation. Carcinogenesis, 2000;21(11):1959-1964. Appel, LJ, Miller, ER, Jee, SH, Stolzenberg, R, Sehlub, J. The effect of dietary patterns on homocysteine. Circulation, 2000;Aug 22,102(8):852-857. Velie, E, Kulldorff, M, Schairer, C, Block, G, Albanes, D, Schatzkin, A. Dietary fat, fat subtypes, and breast cancer in postmenopausal women: a prospective cohort study. Journal of the National Cancer Institute, 2000;92:833-839. Weed, DL. Interpreting epidemiologic evidence: how meta-analysis and causal inference methods are related. International Journal of Epidemiology, 2000;29:387-390. Connor, RJ, Boer, R, Prorok, PC, Weed, DL. An investigation of design and bias issues in case-control studies of cancer screening using microsimulation. American Journal of Epidemiology, 2000;151:991-998. Weed, DL. Epidemiologic evidence and causal inference. Hematology/Oncology Clinics of North America, 2000;14:797-807. Sarna, LP, Brown, JK, Lillington, L, Wewers, ME, Brecht, ML. Tobacco control attitudes, advocacy, and smoking behaviors of oncology nurses. Oncology Nursing Forum, 2000;27:1519-1528. Wewers, ME, Niedig, JL, Kihm, KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV+ smokers. Journal of the Association of Nurses in AIDS Care, 2000;11:37-44. Snively, TA, Ahijevych, K, Bernhard, L, Wewers, ME. Smoking behavior, dysphoric states and the menstrual cycle: results from single smoking sessions and the natural environment. Psychoneuroendocrinology, 2000;25:677-691. Kihm, KE, Ahijevych, K, Ross, R, Wewers, ME. Implementing the AHCPR Smoking Cessation Guideline in a lung cancer surgery clinic. Oncology Nursing Forum, 2000;27:1248-1254. Wewers ME, Ahijevych KL, Chen MS, Dresbach S, Kihm KE, Kuun PA. Tobacco use characteristics among rural Ohio Appalachians. Journal of Community Health, 2000;25:377-388. Sarna LP, Brown JK, Lillington L, Rose M, Wewers ME, Brecht ML. Tobacco interventions by oncology nurses in clinical practice: report from a national survey. Cancer, 2000;89:881-889. Wewers ME, Ahijevych KL, Guthrie R, Kuun PA, Mitchell L, Moeschberger M, Chen MS. Cotinine levels among Southeast Asian smokers. Nicotine and Tobacco Control, 2000;2:85-91. Biometry Research Group:Baker SG. Analyzing a randomized cancer prevention trial with a missing binary outcome, an auxiliary variable, and all-or-none compliance, Journal of the American Statistical Association, 2000, 95, 43-50. Baker,SG and Lindeman, KS. Randomized and nonrandomized studies. Statistical considerations (editorial), Anesthesiology, 2000; 92:928-30. Baker SG. Identifying combinations of cancer biomarkers for further study as triggers of early intervention, Biometrics, 2000; 56:1082-1087. Berger, VW. Pros and Cons of Permutation Tests, Statistics in Medicine, 2000, 19, 1319-1328. Berger, VW. and Ivanova, A. Bias of Linear Rank Tests for Stochastic Order in Ordered Categorical Data, Journal of Statistical Planning and Inference, 2000, in press. Permutt, T. and Berger, VW. Rank Tests in Ordered 2xk Contingency Tables, Communications in Statistics, Theory and Methods, 2000, 29, 5, 989-1003. Berger, VW. Critique of Ludbrook and Dudley, American Statistician, 2000, 54, 1, 85-86. Berger, VW. and Ivanova, A. Permutation Tests in S-PLUS for Phase III Clinical Trials. In Using S-PLUS in the Pharmaceutical Industry, S. P. Millard (Editor), Springer Verlag, New York, 2000. Kulldorff, M, McShane LM, Schatzkin, A, Freedman LS, Wargovich, MJ, Woods, C, Purewal, M, Burt,W, Lawson, M, Mateski, DJ, Lanza, E, Corle, DK, O'Brien, B, Moler, J. Measuring cell proliferation in the rectal mucosa. comparing bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) assays. J Clin Epidemiol 2000;53(8):875-83. Schatzkin, A, Lanza, E, Corle, D, Lance, P, Iber, F, Caan, B, Shike, M, Weissfeld, J, Burt, R, Cooper, MR, Kikendall, JW, Cahill, J, The Polyp Prevention Trial Study Group. Lack of effect of a low-fat, high-fiber, fruit- and vegetable-enriched diet on the recurrence of colorectal adenomas. N Engl J Med2000;342(16):1149-55. Buyske, S, Fagerstrom, R, Ying, Z. A class of weighted log-rank tests for survival data when the event is rare. Journal of the American Statistical Association, 2000, 95:249-258. Hasson, MA, Fagerstrom, RM, Kahane, DC, Walsh, JH, Myers, MH, Caughman, C, Wenzel, B, Haralson, JC, Flickinger, LM & Turner, LM. Design and Evolution of the Data Management Systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Controlled Clinical Trials, 21(6S):329S-348S. Weissfeld, JL, Fagerstrom, RM & O'Brien, B. Quality Control of Cancer Screening Examination Procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 21(6S): 390S-399S. Marcus, PM, Bergstralh, EJ, Fagerstrom, RM, Williams, DE, Fontana, R, Taylor, WF, Prorok, PC. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst, 2000;92:1308-1316. Stein, MD, Rich, JD, Maksad, J, Chen, M, Hu, P, Sobota, M, Clarke, J. Adherence to antiretroviral therapy among HIV-infected methadone patients: Effects of ongoing illicit drug use. Am J Drug Alcohol Abuse, 2000, 26(2):195-205. Havlik, RJ, Izmirlian, G, Petrovitch, H, Ross, GW, Masaki, K, Curb, JD, Saunders, AM, Foley, DJ, Brock, D, Launer, LJ & White, L. APOE -4 predicts incidence AD in Japanese-American men: The Honolulu-Asia aging study. Neurology, 2000, 54:1526-1529. Izmirlian, G, Brock, D, Ferrucci, L & Phillips, C. Active life expectancy for annual follow-updata with missing responses. Biometrics, 2000, 56:244-248. Izmirlian, G, Brock, D & White, L Estimating incidence of dementia subtypes: Assessing the impact of missed cases. Statistics in Medicine, 2000, 19:1577-1591. Leveille, SG, Penninx, BWJ, Melzer, D, Izmirlian, G & Guralnik, JM. Sex differences in the prevalence of mobility disability in old age: The synamics of incidence, recovery, and mortality. Journal of Gerontology: Social Sciences, 2000, 55B(1)S41-S50. Masaki, KH, Losonczy, KG, Izmirlian, G, Foley, DJ, Ross, GW, Petrovitch, H, Havlik, R & White, LR. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology, 2000, 54:1265-1272. Petrovitch, H, White, LR, Izmirlian, G, Ross, GW, Havlik, RJ, Markesbery, W, Nelson, J, Davis, DG, Hardman, J, Foley, DJ & Launer, LJ. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Neurobiology of Aging, 2000, 21:57-62. Marcus, PM, Vineia, P, Rothman, N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 studies. Pharmacogenetics, 2000, 10:115-122. Marcus, PM, Television as a venue for cancer education: the General Hospital experience. Journal of Cancer Education, 2000, 15:4. Marcus, PM, Hayes, RB, Vineis, P, Garcia-Closas, M, Caporaso, NE, Autrup, H, Branch, RA, Brockmoller, J, Ishizaki, T, Karakaya, AE, Ladero, JM, Mommsen, S, Okkels, H, Roots, I, Rothman, N. The interactive effect of NAT2 acetylation status and cigarette smoking on bladder cancer risk: A case-series mata-analysis. Cancer Epidemiology, Biomarkers and Prevention, 2000, 9:461-467. Marcus, PM, Newman, B, Millikan, RC, Moorman, PG, Baird, DD, Qaqish, B. The association of adolexcent cigarette smoking, alsoholic beverage consumption, environmental tobacco smoke, and ionizing rediation with subsequent breast cancer risk. Cancer Causes and Control, 2000, 11:271-278. Hartge, P, Hayes, R, Reding, D, Sherman, ME, Prorok, P, Schiffman, M, Buys, S. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial. Am J Obstet Gynecol. 2000;183(5):1232-1237. Gohagan, JK, Levin, DL, Prorok, PC, Sullivan, D. (eds). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials Supplement, 2000;21(6S):249S-406S. Gohagan, JK, Prorok, PC, Hayes, R, Kramer, BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, organization, and status. Controlled Clin Trials Supplement 2000;21(6S):251S-272S. Prorok, PC, Andriole, GL, Bresalier, R, Buys, S, Chia, D, Crawford, ED, Fogel, R, Gelmann, EP, Gilbert, F, Hasson, MA, Hayes, R, Johnson, CC, Mandel, JS, O'Brien, B, Oken, M, Rafla, S, Reding, D, Rutt, W, Weissfeld, JL, Yokochi, L, Gohagan, JK. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials Supplement 2000;21(6S):273S-309S. O'Brien, B, Nichaman, L, Browne, JEH, Levin, D, Prorok, PC, Gohagan, JK. Coordination and management of a large multicenter screening trial: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials Supplement 2000;21(6S):310S-328S. Cancer Biomarkers Research GroupNegm, R. S., Verma, M., and Srivastava, S. 2002. The Promise of Biomarkers in Cancer Screening and Detection. Trends in Mol. Med. Trends in Molecular Medicine, 2002, 8:6:288-293. Verma, M., Negm, R.S., and Srivastava, S. 2002. The NCI EDRN Approach to Molecular Targets for Earlier Cancer Detection and Identification of Risk. J. Clin. Lig. Assay. Spring, 25:1, 1-5. Baker SG, Kramer BS, Srivastava S. Markers for early detection of cancer: Statistical guidelines for nested case-control studies. BMC Med Res Methodol. 2002;2:4. Baker S, Srivastava S, Kramer BS. Markers for Early Detection of Cancer: Statistical Guidelines for Retrospective Longitudinal Studies. BMC Medical Research Methodology. 2002; 2:1-8. Kutkat L, Srivastava S. The Early Detection Research Network: A platform for communication and collaboration. Disease Marker. 2001; 17: 3-4. Mills GB, Bast RC, Srivastava S. Future of Ovarian cancer Screening: From Emerging Technology of Transcriptional Profiling and Proteomics. J Natl. Cancer Inst. 2001; 93, 1437-39. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr. Proteomics in early detection of cancer. Clin Chem. 2001 Oct;47(10):1901-11. Srinivas PR, Barker P, Srivastava S. Nanotechnology in early detection of cancer. Lab Invest. 2002 May;82(5):657-62. Srivastava S, Kramer BS. Early detection cancer research network. Lab Invest. 2000 Aug;80(8):1147-8. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res. 2001; 7:1118-26. Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci. 2001 Sep;945:103-15. Verma M, Lambert PF, Srivastava SK. Meeting highlights: National Cancer Institute workshop on molecular signatures of infectious agents. Dis Markers. 2001;17(3):191-201. Srinivas P, Kramer BS, Srivastava S. Trends in biomarker research for cancer detection. Lancet Oncol. 2001; Nov;2(11):698-704. Verma M, Srivastava S. Molecular Signatures of Infectious Agents in Human Cancer. Disease Markers. 2001; 17:121-122. Verma M, Lambert P, Srivastava S. Meeting highlights: National Cancer Institute workshop on molecular signatures of infectious agents. Disease Markers. 2001; 17: 191-201. Srivastava S, Kramer, BS. Early Detection Research Network (editorial), Laboratory Investigations, 2000, 80, 1147-1148 Albores-Saavedra, J, Murakata, L, Krueger, JE, Henson,DE. Noninvasive and minimally invasive papillary carcinomas of theextrahepatic bile ducts.Cancer, 2000, 89:508-515. Bast, RC, Berchuck, A, Burke, HG, Buller, RE...Henson, DE...Wilbanks, GD. Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the consensus meeting organized by the European Society of Gynecological Oncology (ESGO). Eur J Gynace Oncol, 2000, 21:513-526. Albores-Saavedra, J, Henson, DE, Klimstra, DS. Atlas of Tumor Pathology: Tumors of the Gallbladder, Extrahepatic Bile Ducts, and Ampulla of Vater. Series 3, Armed Forces Institute of Pathology, Washington DC, 2000. Henson, DE, Albores-Saavedra, J, eds, Pathology of Incipient Neoplasia, 3rd edition, Oxford University Press, New York, 2000. Misra, RR, Pinsky, PF, Srivastava, S. Prognostic factors for hematologic cancers. Hematology/Oncology Clinics of North America. 2000;14:907-924. Banerjee, HN & Verma, M, Search for a novel killer toxin in yeast Pichia pastrois, Plasmid, 2000, 43:181-183. Verma, M & Srivastava, SK, Early Detection. Cancer Research - An Encyclopedia Reference, Springer Press, Germany, 2000. Kalebic, T, Verma, M & Srivastava, S, Biomarkers of preneoplasia. In: Cancer Prevention and Control P. Greenwald, BS Kramer & D Weed Eds., 2000. Verma, M &Srivastava, SK, Enzymeimmunoassay, In Encyclopedia of Public Health, New York:Elly Dickson Publisher, 2000. Chemoprevention Agent Development Research GroupArif JM, Gairola CG, Kelloff GJ, Lubet RA, Gupta RC. Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. Mutat Res. 2000, 452(1):11-18. Boone CW, Kelloff GJ. Endpoint markers for cancer chemoprevention trials derived from the lesion of precancer (intraepithelial neoplasia) measured by computer-assisted quantitative image analysis. J Cell Biochem Suppl, 2000, 34:67-72. Review. Boone CW, Stoner GD, Bacus JV, Kagan V, Morse MA, Kelloff GJ, Bacus JW. Quantitative grading of rat esophageal carcinogenesis using computer-assisted image tile analysis. Cancer Epidemiol Biomarkers Prev. 2000, 9(5):495-500. Chow HH, Earnest DL, Clark D, Mason-Liddil N, Kramer CB, Einspahr JG, Guillen-Rodriguez JM, Roe DJ, Malone W, Crowell JA, Alberts DS. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev. 2000, Apr;9(4):351-6. Christov K, Shilkaitis A, Green A, Mehta RG, Grubbs C, Kelloff G, Lubet R. Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole. Breast Cancer Res Treat. 2000, 60(2):117-28. D'Agostini F, Balansky R, Pesce C, Fiallo P, Lubet RA, Kelloff GJ, DeFlora S. Induction of alopecia in mice exposed to cigarette smoke. Toxicol Lett. 2000, 114(1-3):117-23. D'Ambrosio,S.M., D'Ambrosio,R.G., Milo,G.E., Casto,B.C., Kelloff,G.J., Steele,V.E. Differential responses of normal, premalignant, and malignant human oral epithelial cells by chemopreventive agents. AntiCancer Research 2000, 20(4): 2273-2280. Elmore E, Luc TT, Li HR, Buckmeier JA, Steele VE, Kelloff GJ, Redpath JL. Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data. Anticancer Res 2000,. Jan-Feb;20(1A):27-32. Elmore E, Luc TT, Steele VE, Kelloff GJ, Redpath JL. The human epithelial cell cytotoxicity assay for determining tissue specific toxicity. Methods Cell Sci 2000, 22(1):17-24. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM., Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000, 21(7):1271-9. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 2000, 60(7):1864-70. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000, 78:199-334. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. (2000) Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr. 2000 Feb;130(2S Suppl):467S-471S. Review. Kelloff GJ, Sigman CC, Johnson KA, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):127-37. Review. Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis, 2000, 21(1):113-6. Lawrence JA, Malpas PB, Sigman CC, Kelloff GJ. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. J Cell Biochem Suppl. 2000, 34:103-14. Review. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor,celecoxib, administered during different stages of carcinogenesis..Cancer Res., 2000, Jan 15;60(2):293-7. Reddy BS, Hirose Y, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Lack of chemopreventive efficacy DL-selenomethionine in colon carcinogenesis. Int J Mol Med. 2000, Apr;5(4):327-30. Shilkaitis A, Green A, Steele V, Lubet R, Kelloff G, Christov, K. Neoplastic transformation of mammary epithelial cells in rats is associated with decreased apoptotic cell death. Carcinogenesis, 2000, 21(2):227-233. Shilkaitis, A., Graves, J., Mehta, R., Hu, L., You, M., Lubet, R., Steele, V., Kelloff, G., Christov, K. Bcl-2 and Bax are differentially expressed in hyperplastic, premalignant, and malignant lesions of mammary carcinogenesis. Cell Growth & Differentiation, 2000, 11:437-445. Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., Sigman, C.C., and Kelloff, G.J. Potential use of lipoxygenase inhibitors for cancer chemopreventions. Exp. Opin. Invest. Drugs, 2000, 9(9):2121-2138 Steele VE, Kelloff GJ, Balentine D, Boone CW, Mehta R, Bagheri D, Sigman CC, Zhu S,Sharma S. Comparative chemopreventive mechanisms of green tea, black tea and selected polyphenol extracts measured by in vitro bioassays. Carcinogenesis, 2000, 21(1):63-67. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res, 2000, 6(1):78-89. Wargovich MJ, Jimenez A, McKee K, Steele VE, Velasco M, Woods J, Price R, Gray K, Kelloff GJ. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis. 2000, 21(6):1149-55. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, Kelloff GJ. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis, 2000, 21(2):179-182. Zhang Z, Liu Q, Lantry LE, Wang Y, Kelloff GJ, Anderson MW, Wiseman RW, Lubet RA, You M. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res.2000, 60(4):901-7. Community Oncology and Prevention Trials Research GroupVarricchio, C., Aziz, N, Rehabilitation and survivorship. In Lenhard, RE, Osteen, RT & Gansler, T (Eds.), Textbook of Clinical Oncology 3rd Edition, American Cancer Society, Atlanta GA, 2000, 823-836. Varricchio, CG, Measurement and assessment. What are the issues? In Winningham, ML, Barton-Burke, M. (Eds.) Fatigue in Cancer. A Multidimensional Approach. Boston MA: Jones and Bartlett Pub, 2000, 55-68. Early Detection Research GroupGohagan JK, Levin DL, Prorok PC, Sullivan D, eds. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials (suppl) 2000;21(6S):249S-406S. Gohagan, JK, Prorok, PC, Hayes, R. & Kramer, BS. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: History, Organization, and Status. Controlled Clinical Trials, 2000, 21(6S):251S-272S. Prorok, PC, Andriole, GL, Bresalier, R, Buys, S, Chia, D, Crawford, ED, Fogel, R, Gelmann, EP, Gilbert, F, Hasson, MA, Hayes, R, Johnson, CC, Mandel, JS, Oberman, A, O'Brien, B, Oken, M, Rafla, S, Reding, D, Rutt, W, Weissfeld, JL, Yokochi, L, & Gohagan, JK. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clinical Trials, 2000, 21(6S):273S-309S. O'Brien, B, Nichaman, L, Browne,JEH, Levin, D, Prorok, PC & Gohagan, JK. Coordination and Management of a Large Multicenter Screening Trial: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Controlled Clinical Trials, 2000, 21(6S):310S-328S. Hayes, RB, Reding, D, Kopp, W, Subar, AF, Bhat, N, Rothman, N, Caporaso, N, Ziegler, R, Johnson, CC, Weissfeld, J, Hoover, RN, Hartge, P, Palace, C & Gohagan, JK, Etiologic and Early Marker Studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Controlled Clinical Trials, 2000, 21(6S):349S-355S. Simpson, NK, Johnson, CC, Ogden, S, Gamito, E, Trocky, N, McGuire, C, Martin, J, Barrow, S, Lamerato, L, Flickinger, LM, Broski, KG, Engelhard, D, Hilke, C, Bonk, J, Gohagan, B, Gren, L, Childs, J, Lappe, K, Fouad, M, Thompson, J & Sullivan, D. Recruitment Strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: The First Six Years. Controlled Clinical Trials, 2000, 21(6S):356S-378S. Pinsky, PF. Does hereditary nonpolyposis colorectal cancer explain the observed excess risk of colorectal cancer associated with family history? Epidemiology, 2000, 11:297-303. Pinsky, PF, A multi-stage model of adenoma development. Journal of Theoretical Biology, 2000, 207:129-143. Nutritional Sciences Research GroupKnowles, L. and Milner, J.A.. Diallyl Disulfide Increases Cyclin B1 Protein Expression, Decreases p34cdc2 Complex Formation and Hyperphosphorylates p34cdc2 in Human Colon Tumor Cells. Carcinogenesis; 2000, 21(6):1129-34. Knowles, LM, Milner, JA Allyl sulfides modify cell growth. Drug Metabol Drug Interact, 2000, 71(1-4): 81-107. Greenwald, P & Milner, J. Nutrition: A major player in chronic disease. The Chronicle of Higher Education, 2000. Greenwald, P, Milner, JA, Clifford, CK. Creating a new paradigm in nutrition research within the National Cancer Institute, Journal of Nutrition, 2000, 130(12):3103-3105. Ross, SA, McCaffery, PJ, Drager, UC & DeLuca, LM. Retinoids in embryonal development. Physiol. Reviews, 2000, 80:1021-1054. Ross, S. Functional foods: The Food and Drug Administration perspective, American Journal of Clinical Nutrition, 2000, 71(suppl):1735S-1738S. Basic Prevention Science Research GroupAli, IU. Gatekeeper for endometrium: The PTEN tumor suppressor gene. J Natl Cancer Inst, 2000, 92:861-863. Breast and Gynecologic Cancers Research GroupThe Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group, Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: Baseline data from a randomized trial, J Natl Cancer Inst, 2000, 92(5):397-402. Cox JT, Koutsky L, Schiffman M, Solomon D: Re: Emerging technologies and cervical cancer. J Natl Cancer Inst, 2000; 92(12):1014. Cornelison TL: Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment. Current Opinions in Oncology 2000; 12:466-473. Kelloff GJ, Sigman CC, Johnson KA, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA: Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:127-137. Schiffman, M & Adrianza, ME, ASCUS-LSIL triage study, Acta Cytologica, 2000, 44(5):726-742. Gastrointestinal and Other Cancers Research GroupHawk E, Lippman S: Primary cancer prevention studies. Hematol Oncol Clin North Am:, 2000, 14:809-830, Heath E, Limburg P, Hawk E, Forastiere A: Adenocarcinoma of the esophagus: risk factors and prevention., 14:507-514, 2000. Hawk E, Breslow RA, Graubard B: Male pattern baldness and clinical prostate cancer in the Epidemiologic Follow-up Study of the First National Health and Nutrition Examination Survey. Cancer Epi Biomark Prev, 9:523-527, 2000. Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G, Sherman J, et al: A randomized, double-blind placebo controlled study of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med:342:1946-1952, 2000. Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk E, Lubet RA: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res,: 60:1864-1870, 2000. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al: Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs:9:2121-2138, 2000. Hawk E, Viner J, Lawrence J: Biomarkers as surrogates for cancer development. Current Oncol Reports, 2000,2:1-9. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2S Suppl):467S-471S,2000. van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT: Phase I trial of Exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with Familial Adenomatous Polyposis. Clin Cancer Res, 6:78-89, 2000. Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA: Perspectives on surrogate endpoints in the development of drugs that reduce the risk of cancer. In press. Cancer Epi Biomark Prev 9:127-127, 2000. Shinohara H, Fan D, Ozawa S, Yano S, van Arsdell M, Viner JL, Beers R, Pastan I, and IJ Fidler: Site specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin. Int J Oncol 17:643-651, 2000 Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, and I Pastan: Antitumor activity of K1LysPE38QQR, an immunotoxin that targets mesothelin, a cell-surface antigen overexpressed in ovarian cancer and mesothelioma. J Immunotherapy 23(4):473-479, 2000. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 18:3964-73, 2000. Edelmann, W, Umar, A, Yang, K., Heyer, J, Kucherlapati, M, Lia, M, Kneitz, B, Avdievich, E, Wong, E, Kunkel, TA, Lipkin, M, Crouse, G, Kolodner, R, and Kucherlapati, R: The DNA mismatch repair gene MSH3 is cooperating in tumor suppression. Cancer Research, 60:803-807, 2000. Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett JC, Kunkel TA, Koi M: Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol. Carcinog. 29:37-49, 2000. Lung and Upper Aerodigestive Cancers Research GroupChang, T-H & Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor y in onn-small cell lung cancer. Cancer Research, 2000, 60:1129-1138. Chang, T-H & Szabo, E. Peroxisome proliferator-activated receptor y and the induction of differentiation in non-small cell lung cancer. Cancer Research Alert, 2000, 2:32-35. Linnoila, RI, Szabo, E, DeMayo, F, Witschi, H, Sabourin, C & Malkinson, A. The role of CC10 in pulmonary carcinogenesis: From a marker to tumor suppression. Annals of the New York Academy of Sciences, 2000, 923:249-267. Prostate and Urologic Cancers Research GroupBrawley OB and Parnes, H: Prostate Cancer Prevention trials in the USA. European Journal of Cancer; 36(10):1312-1315, 2000. |
|
|
|
        
|
|
|
||||||
|
||||||
|
||||||
HOME | DICTIONARY | SITE MAP | SEARCH |
||||||
|
||||||
|
||||||
 |